A retrospective study by IDIBELL and the Hospital Universitario de Bellvitge with 144 cases shows that intravenous treatment with lacosamide and phenytoin is effective and safe.
A new study on the effectiveness of two intravenous treatments for trigeminal neuralgia Read More »
The runners resolved to collect 5,000 euros for ALS research at IDIBELL and the Bellvitge University Hospital. In exchange, they promised to complete the Marathon.
Six runners complete the Zurich Marató de Barcelona and raise funds for ALS research Read More »
The Daniel Bravo Andreu Private Foundation has awarded its grants for biomedical research stays at benchmark centres abroad to PhD candidate Carles Diez of Bellvitge University Hospital–Bellvitge Biomedical Research Institute (IDIBELL)
The “Elles contra ELA” solidarity campaign begins today with the aim of raising awareness about ALS and raising funds for research. This project is promoted by the research group on neurological and neurogenetic diseases of the Bellvitge Biomedical Research Institute (IDIBELL), with the support of the Catalan Foundation of ALS Miquel Valls, the sponsorship of
The solidarity campaign “Elles contra l’ELA” kicks off Read More »
This new CRISPR-Cas9 tool can modify gene sites that were inaccessible until now, which bypasses the limited capabilities of gene editing and reinforce precision medicine.
A new system expands the gene-editing possibilities in animals Read More »
The protein can slow down the proinflammatory activity of the immune cells and, therefore, stop their body attack.
It begins the selection of candidates to carry out a doctoral program in Regenerative Medicine between the SZBL and the IDIBELL. The program will run mainly at SZBL and will have a minimum six months stay at IDIBELL.
Begins the exchange program between IDIBELL and SZBL Read More »
The analysis show that these vaccines are safe and able to generate immunity in three out of four patients with immune system defects from birth, and in almost all patients treated with immunosuppressants who were evaluated in the study.
SARS-CoV-2 vaccines are safe and effective in people with immunodeficiency Read More »
Preliminary results show that the virus is active, reaches the primary tumor and metastases, and triggers the immune system response. In addition, at recommended doses, it has no important adverse effects.
Lack of family and social support and depressive symptoms are the main factors that impair patients’ ability to adopt healthy habits and practices.
